Acadia Pharmaceuticals' CEO on Rebranding and Using AI
Acadia Pharmaceuticals CEO Catherine Owen Adams discusses the company's recent rebrand and expansion into rare disease marketing, highlighting the role of AI in their strategy.
Neurological biotech Acadia Pharmaceuticals has rolled out a rebrand as it seeks to expand into the rare disease space, with AI playing a major role in their marketing strategy.
MM+M spoke with Acadia CEO Catherine Owen Adams on the company's recent rebrand, its expansion into rare disease and how it's using AI throughout commercialization and marketing.
Adams shares her insights on the benefits and challenges of marketing as a smaller biotech and how her marketing background is helping to steer the company into 2026.
This interview has been edited lightly for length and clarity.
Author's summary: Acadia Pharmaceuticals rebrands and expands into rare disease marketing with AI.
More News
- Prop 50 co-author Assemblymember Gregg Hart urges people to vote | News Channel 3-12
- Prop 50 Could Affect California and Future Elections – What Do You Think? | News Channel 3-12
- There’s math behind this maddening golf mishap
- Pacific Power 'prepared to respond to weather-related outages' ahead of forecast storm
- 2025 East Cobb Election Results: Georgia PSC; Marietta City